Gilead Sciences & Second Genome Announce Strategic Collaboration in Biomarker and IBD Drug Discovery
Gilead Sciences, Inc. (Nasdaq: GILD) and Second Genome, a leader in microbiome science, today announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to […]
